Platelet factor 4 triggers thrombo‐inflammation by bridging innate and adaptive immunity
Open Access
- 7 May 2023
- journal article
- review article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 45 (S2), 11-22
- https://doi.org/10.1111/ijlh.14075
Abstract
Platelet factor 4 (PF4, synonym: CXCL4) is an evolutionary old chemokine with proposed roles in hemostasis and antimicrobial defense. In addition, PF4 has attracted considerable attention as a crucial mediator of one of the most prothrombotic adverse drug effects affecting blood cells, heparin-induced thrombocytopenia (HIT). Interest in PF4 substantially increased in 2021 when it was identified as the target antigen in the life-threatening adverse effect, vaccine-induced immune thrombotic thrombocytopenia (VITT). We address the concept that a major biological function of PF4-a strongly cationic chemokine-is to bind to negatively-charged prokaryotic microorganisms, resulting in structural changes in PF4 that trigger a danger signal recognized by the adaptive immune system. Application of biophysical tools has provided substantial insights into the molecular mechanisms by which PF4 becomes immunogenic, providing insights into a new mechanism of autoimmunity. Binding of autoantibodies with high affinity induces conformational change(s) in the endogenous protein, which are then recognized as foreign antigen, as exemplified by the prothrombotic disorders, autoimmune HIT and VITT. The final part of our review summarizes current assays for HIT and VITT, explaining how structural aspects of anti-PF4 pathobiology relate to assay design and performance characteristics. Currently, functional (platelet activation) assays using washed platelets detect HIT antibodies when heparin is added, and VITT antibodies when PF4 is added. Solid-phase PF4-dependent immunoassays using microtiter plates are sensitive for both HIT and VITT antibodies, while rapid immunoassays, in which the PF4/heparin antigen is coated on beads, are sensitive and specific for HIT, but not for VITT antibodies.This publication has 82 references indexed in Scilit:
- Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopeniaBlood, 2012
- Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patientsHaematologica, 2011
- Association of natural anti-platelet factor 4/heparin antibodies with periodontal diseaseBlood, 2011
- Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopeniaBlood, 2011
- Platelet Factor 4/Heparin Antibodies in Blood Bank DonorsAmerican Journal of Clinical Pathology, 2010
- Determinants of PF4/heparin immunogenicityBlood, 2007
- Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearanceBlood, 2006
- Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT AntibodiesArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopeniaBlood, 2005
- Interactions of Platelet Factor 4 with the Vessel WallSeminars in Thrombosis and Hemostasis, 2004